Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization Review


Authors: Chen, J.; Lazarus, H. M.; Dahi, P. B.; Avecilla, S.; Giralt, S. A.
Review Title: Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization
Abstract: Hematopoietic cell transplantation (HCT) has become a primary treatment for many cancers. Nowadays, the primary source of hematopoietic cells is by leukapheresis collection of these cells from peripheral blood, after a forced egress of hematopoietic cells from marrow into blood circulation, a process known as “mobilization”. In this process, mobilizing agents disrupt binding interactions between hematopoietic cells and marrow microenvironment to facilitate collection. As the first essential step of HCT, poor mobilization, i.e. failure to obtain a desired or required number of hematopoietic cell, is one of the major factors affecting engraftment or even precluding transplantation. This review summarizes the available mobilization regimens using granulocyte-colony stimulating factor (G-CSF) and plerixafor, as well as the current understanding of the factors that are associated with poor mobilization. Strategies to mobilize patients or healthy donors who failed previous mobilization are discussed. Multiple novel agents are under investigation and some of them have shown the potential to enhance the mobilization response to G-CSF and/or plerixafor. Further investigation of the risk factors including genetic factors will offer an opportunity to better understand the molecular mechanism of mobilization and help develop new therapeutic strategies for successful mobilizations. © 2020
Keywords: treatment response; unclassified drug; fludarabine; lenalidomide; review; nonhuman; cancer radiotherapy; cytarabine; antineoplastic agent; heredity; multiple myeloma; bone marrow suppression; nausea; vomiting; cyclophosphamide; melphalan; bone pain; hematopoietic stem cell transplantation; transplantation; risk factor; carmustine; ewing sarcoma; patient care; neuroblastoma; blood analysis; diabetes mellitus; stem cell mobilization; headache; hematopoietic stem cell; granulocyte colony stimulating factor; plerixafor; autologous hematopoietic stem cell transplantation; chlorambucil; sickle cell anemia; musculoskeletal pain; pegfilgrastim; desipramine; human; priority journal; daratumumab; balixafortide; lgb 321; n (benzenesulfonyl) levo prolyl levo 2 (1 pyrrolidinylcarbonyl) tyrosine
Journal Title: Blood Reviews
Volume: 47
ISSN: 0268-960X
Publisher: Churchill Livingstone  
Date Published: 2021-05-01
Start Page: 100771
Language: English
DOI: 10.1016/j.blre.2020.100771
PUBMED: 33213986
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 June 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sergio Andres Giralt
    1053 Giralt
  2. Parastoo Bahrami Dahi
    295 Dahi
  3. Jian Chen
    5 Chen